Open Label Study Telmisartan and Amlodipine in Hypertension

This study is currently recruiting participants.

Verified by Boehringer Ingelheim Pharmaceuticals, December 2008

Sponsored by:	Boehringer Ingelheim Pharmaceuticals
Information provided by:	Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00614380

Purpose

The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations T40/A5 or T80/A5 during long-term open-label treatment.

Condition	Intervention	Phase
Hypertension	Drug: telmisartan/amlodipine 40/5 mg fixed combination Drug: telmisartan/amlodipine 80/5 mg fixed combination	Phase III

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Telmisartan Amlodipine Amlodipine besylate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Safety/Efficacy Study
Official Title:	An Open Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Combination of Telmisartan 40mg + Amlodipine 5mg or the Combination of Telmisartan 80mg + Amlodipine 5mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Primary Outcome Measures:

The primary endpoint is the proportion of patients achieving DBP control [ Time Frame: Six months ]

Secondary Outcome Measures:

change from baseline in seated through DBP change frmo baseline in seated SBP proportion of patients achieving DBP response proportion of patients achieving SBP response [ Time Frame: Six months ]

Estimated Enrollment:	974
Study Start Date:	January 2008
Estimated Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

patients aged at least 18 years
diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the preceding trial.
failure to respond to six weeks treatment with A5 in the run-in period of the preceding trial.

Exclusion Criteria:

pre-menopausal women who are not surgically sterile; or are nursing or pregnant; or are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study
development of any medical condition in the preceding trial that in the investigator's opinion could be worsened by treatment with either T40/A5 or T80/A5
discontinuation from the preceding trial because of any adverse event or any other reason
known or suspected secondary hypertension
mean seated SBP => 180 mmHg and/or mean seated DBP => 120 mmHg at any visit

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00614380

Contacts

Contact: Boehringer Ingelheim Study Coordinator

800-542-6257 ext Option 4

clintriage.rdg@boehringer-ingelheim.com

Show 122 Study Locations

Sponsors and Collaborators

Boehringer Ingelheim Pharmaceuticals

Investigators

Study Chair:

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals

More Information

Responsible Party:	Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair )
Study ID Numbers:	1235.7, EUDRACT2007-002410-19
Study First Received:	January 28, 2008
Last Updated:	December 17, 2008
ClinicalTrials.gov Identifier:	NCT00614380
Health Authority:	Belgium: Federal Agency for Medicines and Health Products; Canada: Health Canada (TPD); Denmark: Lægemiddelstyrelsen, Kliniske forsøg, Inspektionen Axel Heides Gade 1, DK-2300 Copenhagen S; Finland: National Agency for Medicines; France: AGENCE FRANCAISE DE SECURITE SANITAIRE DES PRODUITS DE SANTE; Korea, Republic of: Korea Food and Drug Administration (KFDA); Netherlands: Central Committee on Research involving Human Subjects (CCMO); Norway: Norwegian Medicines Agency (Statens Legemiddelverk); Philippines: Department of Health, Republic of the Philippines; South Africa: Medicines Control Council; Sweden: Regional Ethics Committee of Stockholm, PO Box 289, SE-17177 Stockholm, Sweden. Medical Products Agency; Taiwan: Department of Health, Executive Yuan, Taiwan; United States: Food and Drug Administration

Study placed in the following topic categories:

Calcium, Dietary
Vascular Diseases
Telmisartan

Angiotensin II
Amlodipine
Hypertension

Additional relevant MeSH terms:

Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Calcium Channel Blockers
Enzyme Inhibitors
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

Protease Inhibitors
Membrane Transport Modulators
Angiotensin II Type 1 Receptor Blockers
Therapeutic Uses
Angiotensin-Converting Enzyme Inhibitors
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009